科源制药

301281.SZ

Wind Industry: 医疗保健 > 医药生物 > 制药 > 西药

公司成立于2004年，位于济南商河经济开发区，是国家高新技术企业、力诺集团健康产业核心成员企业、山东省化学合成药物骨干企业。2016年2月，公司在全国中小企业股份转让系统成功挂牌上市。2023年4月4日，公司在深圳证券交易所挂牌上市。公司是国内化学原料药细分赛道龙头企业，产品覆盖降糖类、麻醉类、心血管及中枢神经类等慢性疾病领域。公司专注于化学原料药及其制剂产品的研发、生产与销售，所有产品均通过国家GMP认证，核心产品拥有欧盟CEP证书，先后通过了美国FDA、日本PMDA、韩国MFDS等多国官方药政认证。在深交所创业板成功上市后，公司开启了数智、资本双轮驱动的高速发展阶段，业务范围遍及全球数十个国家和地区。近年来，公司以“用数智医药守护生命健康”为使命，不断强化“一体两翼三支柱”发展策略，凭借技术研发、数智制造、文化营销三大支柱，落实数智化经营、数智化服务、数智化获客，赓续“健康中国用心承诺”血脉，打造中国数智医药创新品牌。

ESG Score Industry Ranking:
9 / 282 (制药)

ESG Rating Distribution(制药)

0.35%

AAA

2.84%

17.73%

20.21%

BBB

30.14%

24.11%

0.35%

CCC

Trend of Rating

About Wind ESG Rating

Wind has developed a rigorous rating methodology based on the core connotations of ESG, aligning with international standards and frameworks, and incorporating the characteristics of Chinese companies, to assess the company's essential ESG performance, risk and its ability to operate sustainably.

Focusing on the ESG risks and opportunities of each industry, the companies are rated on a AAA-CCC scale relative to the performance of their industry peers. Wind ESG rating is updated annually or in response to major changes.

The Wind ESG Rating Issuer Communication Platform (esg.wind.com.cn) is now available. Rated companies can access their detailed rating information through this platform, and communicate with or provide feedback to the Wind ESG Rating team regarding specific rating components. For any additional questions, please feel free to send an email to GR.ESG@wind.com.cn.

ESG Score

ESG Score：7.99Updated on 2026-10-29

07.9910

Management & Practices Score：4.99Updated on 2026-10-16

04.997

Controversies Score：2.99Updated on 2026-10-29

02.993

ESG Score Comparison

Indicator	Company Score	Industry Average	Weight
Environmental	5.58	3.56	22.85%
Social	7.51	3.72	49.76%
Governance	7.72	5.34	27.39%

Wind ESG Rating Framework

Building on the foundation of domestic and international ESG policies and standards, our proprietary ESG rating framework considers the development of Chinese capital market and integrates the characteristics of the Chinese companies in various industries. The Wind ESG Rating framework is composed of management & practice and controversies assessment, including:

500+ management & practices indicators, covering E, S and G pillars, reflecting long-term ESG fundamental impacts
1,200+ risk labels, covering news, regulatory penalties and lawsuits, reflecting impact of short-term risks

Management & practice score is the weighted summation of E, S and G pillar scores. The weights reflect both the relative impact of each issue within each industry and the negative or positive contribution of each industry to the environment and society relative to other industries.

Controversies score and ESG score are updated daily, E, S and G pillar scores and management & practice score are updated with underlying data, corresponding data are released on various channels, including Wind Financial Terminal.

Explore More

Wind ESG Rating Methodology.pdf1,198KB Wind ESG Ratings FAQs.pdf755KB

More Details

Peer Comparison(282 companies in the industry) ?

Ranking	Code	Security Name	ESG Rating	ESG Score	Controversies Score	Management & Practices Score	Environmental	Social	Governance
1	600535.SH	天士力	AAA	8.94	3.00	5.94	9.07	8.63	7.75
2	301130.SZ	西点药业	AA	8.39	3.00	5.39	7.28	7.78	7.92
3	3320.HK	华润医药	AA	8.31	3.00	5.31	7.23	7.73	7.62
4	600380.SH	健康元	AA	8.22	3.00	5.22	5.64	8.16	7.66
5	603896.SH	寿仙谷	AA	8.18	3.00	5.18	6.54	7.51	7.92
6	600329.SH	达仁堂	AA	8.15	3.00	5.15	6.24	7.44	8.16
7	601607.SH	上海医药	AA	8.07	3.00	5.07	7.19	7.17	7.40
8	000999.SZ	华润三九	AA	8.03	3.00	5.03	7.66	7.39	6.42
9	301281.SZ	科源制药	A	7.99	2.99	4.99	5.58	7.51	7.72
10	000513.SZ	丽珠集团	AA	7.94	2.99	4.94	5.51	7.94	6.76